Maryam Osooly

Loss of Parkinson’s susceptibility gene LRRK2 promotes carcinogen-induced lung tumorigenesis

Chandra B Lebovitz, Nicole Wretham, Maryam Osooly et al. · Scientific Reports · 2021 · 35 citations · Full text

Medicine, Genetics, Oncology +17

Characterization of Long-Circulating Cationic Nanoparticle Formulations Consisting of a Two-Stage PEGylation Step for the Delivery of siRNA in a Breast Cancer Tumor Model

Emmanuel A. Ho, Maryam Osooly, Dita Strutt et al. · Journal of Pharmaceutical Sciences · 2012 · 31 citations

Pharmacy, Molecular Pharmaceutics, Pharmaceutics +16

Topotecan and Doxorubicin Combination to Treat Recurrent Ovarian Cancer: The Influence of Drug Exposure Time and Delivery Systems to Achieve Optimum Therapeutic Activity

Nilesh A. Patankar, Julia Pritchard, Mariska van Grinsven et al. · Clinical Cancer Research · 2013 · 29 citations

Medicine, Oncology, Pharmacology +17

Validating the use of a luciferase labeled breast cancer cell line, MDA435LCC6, as a means to monitor tumor progression and to assess the therapeutic activity of an established anticancer drug, docetaxel (Dt) alone or in combination with the ILK inhibitor, QLT0267

Jessica Kalra, Malathi Anantha, Corinna Warburton et al. · Cancer Biology & Therapy · 2011 · 22 citations · Full text

Medicine, Oncology, Pharmacology +17

Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities

Dawn Waterhouse, Brent W. Sutherland, Nancy Dos Santos et al. · Investigational New Drugs · 2014 · 15 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17